ECOR electroCore

electroCore, Inc. Announces Closing of Initial Public Offering

electroCore, Inc. Announces Closing of Initial Public Offering

BASKING RIDGE, N.J., June 26, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq:ECOR) today announced the closing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $15.00 per share. The proceeds from this offering, net of underwriting discounts and commissions, are approximately $72,540,000. In addition, electroCore has granted the underwriters a 30‑day option to purchase up to an additional 780,000 shares of common stock at the initial public offering price less discounts and commissions.  All shares of common stock in the offering were sold by electroCore.

electroCore’s common stock began trading on the Nasdaq Global Market on June 22, 2018 under the symbol ECOR.

Evercore ISI, Cantor Fitzgerald & Co. and JMP Securities acted as joint book-running managers for the offering. BTIG, LLC acted as lead manager.

A registration statement related to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and was declared effective by the SEC the on June 21, 2018. Copies of the registration statement may be accessed through the SEC’s website at .

The offering was made only by means of a prospectus forming part of the registration statement. Copies of the final prospectus related to the offering may be obtained from: Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by phone at (888) 474-0200, or by email at ; Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 5th Floor, New York, NY 10022, or by phone at (212) 829-7122, or by email at ; or JMP Securities LLC, 600 Montgomery Street, 11th Floor, San Francisco, California 94111, or by phone at (415) 835-8985, or by email at .

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.



About electroCore

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the acute treatment of migraine and episodic cluster headache.

Contacts

Investors:

Greg Chodaczek or Lynn Lewis

Gilmartin Group



(610) 368-6505

or

Media:

Alexandra Canale

GCI Health

(617) 921-9353

EN
26/06/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE

electroCore Announces Fourth Quarter and Full Year 2023 Financial Resu...

electroCore Announces Fourth Quarter and Full Year 2023 Financial Results Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced fourth quarter and full year 2023 financial results. Fourth Quarter 2023 and Recent Highlights Reported record full year of 2023 revenue of $16.0 millio...

 PRESS RELEASE

electroCore to Participate in Upcoming Investor Conferences

electroCore to Participate in Upcoming Investor Conferences ROCKAWAY, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Strategy Officer, Joshua Lev, is scheduled to attend the 36th Annual Roth Conference taking place at The Ritz Carlton Laguna Niguel in Dana Point, California on March 17 – 19, 2024. electroCore will host 1x1 investor meetings on March 18 and 19, 2024. Please contact Roth MKM to schedule a 1x1 meeting. In addition, Dan Goldberger, CEO of elect...

 PRESS RELEASE

electroCore to Announce Fourth Quarter and Full Year Ended December 31...

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024 ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023, after the close of the market on Wednesday, March 13, 2024. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions. Wednesday, March 13, 4:30 PM ...

 PRESS RELEASE

electroCore Expands Intellectual Property Portfolio

electroCore Expands Intellectual Property Portfolio ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID). U.S. Patent No. 11,894,148 entitled “Systems and Methods for Treating Patients With Diseases Associated With Viruses” generally relates to methods for treating disorders with viruses in the COVID f...

 PRESS RELEASE

electroCore Expands Intellectual Property Portfolio

electroCore Expands Intellectual Property Portfolio ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress disorder (PTSD). U.S. Patent No. 11,865,329 entitled “Vagal Nerve Stimulation for Treating Post-Traumatic Stress Disorder” generally relates to methods for treating the symptoms of post-traumatic stress disorder (PTSD) that include applying one o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch